MAIA Biotechnology (MAIA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
19 May, 2026Related party transactions
Radu Vitoc, brother of the CEO, received $286,321 in 2025: $213,000 in cash and 39,000 options valued at $73,321.
In 2024, Radu Vitoc received $242,102: $172,500 in cash and 50,000 options valued at $69,602.
Compensation for Radu Vitoc in both years was stated to be in line with industry standards.
Voting matters and shareholder proposals
Proxies submitted before this amendment remain valid unless changed by shareholders with a later-dated proxy.
Instructions for voting or submitting proxies are detailed in the Proxy Statement.
Partial view of Summaries dataset, powered by Quartr API
Latest events from MAIA Biotechnology
- Ateganosine (THIO) delivers unprecedented efficacy in late-stage cancer trials, targeting major global markets.MAIA
Investor presentation - Advanced Phase 3 NSCLC trial, raised $33M, and reported a $14.3M net loss for H1 2026.MAIAQ2 2026
- Directors elected and auditors ratified, with 61.88% shareholder participation.MAIAAGM 2026
- $33M equity raise boosts cash to $34.4M, funding Phase 3 NSCLC trial; net loss rises to $6.37M.MAIAQ1 2026
- Proxy statement amended to disclose equity compensation plan details and available shares.MAIAProxy filing
- Election of directors and auditor ratification headline the 2026 virtual annual meeting.MAIAProxy filing
- Virtual meeting to elect directors and ratify auditor, with strong governance and director alignment.MAIAProxy filing
- Advanced clinical pipeline and $33M capital raise position company for pivotal 2026 milestones.MAIAQ4 2025
- THIO's pivotal trials show high efficacy in cancer, with major milestones and approvals expected by 2026.MAIABiotech Showcase 2025 Investor Conference